Drugs / KY100001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04906473 | Jul 2021 → Dec 2022 | neoplasm | Kunming Pharmaceuticals, Inc. | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KY100001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04906473 ↗ |
| Route | Oral | “Oral route” NCT04906473 ↗ |